IMUNON INC (IMNN) Stock Fundamental Analysis
NASDAQ:IMNN - Nasdaq - US15117N6022 - Common Stock - Currency: USD
IMNN gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 553 industry peers in the Biotechnology industry. While IMNN seems to be doing ok healthwise, there are quite some concerns on its profitability. IMNN is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
IMNN had negative earnings in the past year.
IMNN had a negative operating cash flow in the past year.
IMNN had negative earnings in each of the past 5 years.
In the past 5 years IMNN always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of IMNN (-259.33%) is worse than 92.04% of its industry peers.
Looking at the Return On Equity, with a value of -3936.99%, IMNN is doing worse than 84.09% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -259.33% | ||
| ROE | -3936.99% | ||
| ROIC | N/A |
ROA(3y)-122.06%
ROA(5y)-90.29%
ROE(3y)-238.61%
ROE(5y)-173.69%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
IMNN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
IMNN has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, IMNN has more shares outstanding
There is no outstanding debt for IMNN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -78.36, we must say that IMNN is in the distress zone and has some risk of bankruptcy.
IMNN's Altman-Z score of -78.36 is on the low side compared to the rest of the industry. IMNN is outperformed by 95.48% of its industry peers.
IMNN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -78.36 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
IMNN has a Current Ratio of 0.88. This is a bad value and indicates that IMNN is not financially healthy enough and could expect problems in meeting its short term obligations.
IMNN has a worse Current ratio (0.88) than 88.97% of its industry peers.
IMNN has a Quick Ratio of 0.88. This is a bad value and indicates that IMNN is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of IMNN (0.88) is worse than 88.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.88 |
3. Growth
3.1 Past
IMNN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 26.73%, which is quite impressive.
EPS 1Y (TTM)26.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 15.71% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y40.93%
EPS Next 2Y28.4%
EPS Next 3Y18.7%
EPS Next 5Y15.71%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for IMNN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMNN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
IMNN's earnings are expected to grow with 18.70% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.4%
EPS Next 3Y18.7%
5. Dividend
5.1 Amount
No dividends for IMNN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
7.85
+0.64 (+8.88%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners2.35%
Inst Owner Change6.29%
Ins Owners1.34%
Ins Owner Change0%
Market Cap167.21M
Analysts80
Price TargetN/A
Short Float %N/A
Short Ratio0.02
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.46%
Min EPS beat(2)5.34%
Max EPS beat(2)21.57%
EPS beat(4)4
Avg EPS beat(4)12.76%
Min EPS beat(4)5.34%
Max EPS beat(4)21.57%
EPS beat(8)7
Avg EPS beat(8)12.12%
EPS beat(12)8
Avg EPS beat(12)2.45%
EPS beat(16)10
Avg EPS beat(16)-18.26%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-26.79%
PT rev (3m)-24.63%
EPS NQ rev (1m)-30.31%
EPS NQ rev (3m)-17.04%
EPS NY rev (1m)9.86%
EPS NY rev (3m)14.43%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 369.92 | ||
| P/tB | 369.92 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.48
EYN/A
EPS(NY)-0.6
Fwd EYN/A
FCF(TTM)-0.76
FCFYN/A
OCF(TTM)-0.74
OCFYN/A
SpS0
BVpS0.02
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -259.33% | ||
| ROE | -3936.99% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-122.06%
ROA(5y)-90.29%
ROE(3y)-238.61%
ROE(5y)-173.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 117.86% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.88 | ||
| Altman-Z | -78.36 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)77.1%
Cap/Depr(5y)55.66%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.15%
EPS Next Y40.93%
EPS Next 2Y28.4%
EPS Next 3Y18.7%
EPS Next 5Y15.71%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y10.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y17.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.71%
OCF growth 3YN/A
OCF growth 5YN/A